Search research articles
Contact Us
Filters
Showing results (31-40 of 60) with videos related to
Page
of 6
Sort By:
Cells
|
October 5, 2019
Clonal Evolution of <i>TP53</i> c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
Marica Garziera, Erika Cecchin, Giorgio Giorda, et al.
International Journal of Molecular Sciences
|
May 23, 2018
Identification of Novel Somatic <i>TP53</i> Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
Marica Garziera, Erika Cecchin, Vincenzo Canzonieri, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 3, 2011
Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study
Francescapaola Magazzino, Dionyssios Katsaros, Alessandro Ottaiano, et al.
The Oncologist
|
December 8, 2020
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer
Sandro Pignata, Giovanni Scambia, Alessandro Villanucci, et al.
Current Oncology (Toronto, Ont.)
|
July 27, 2022
An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
Michele Bartoletti, Giorgio Giorda, Alessandra Viel, et al.
Cancer Chemotherapy and Pharmacology
|
March 7, 2009
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
Carmela Pisano, Alessandro Morabito, Roberto Sorio, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 20, 2017
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project
Marilena Di Napoli, Chiara Della Pepa, Laura Arenare, et al.
EMBO Molecular Medicine
|
August 6, 2017
CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation
Alessandra Dall'Acqua, Maura Sonego, Ilenia Pellizzari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 2, 2014
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer
Martin R Stockler, Felix Hilpert, Michael Friedlander, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 60) with videos related to
Sort By:
Page
of 6
Cells
|
October 5, 2019
Clonal Evolution of <i>TP53</i> c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
Marica Garziera, Erika Cecchin, Giorgio Giorda, et al.
International Journal of Molecular Sciences
|
May 23, 2018
Identification of Novel Somatic <i>TP53</i> Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
Marica Garziera, Erika Cecchin, Vincenzo Canzonieri, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 3, 2011
Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study
Francescapaola Magazzino, Dionyssios Katsaros, Alessandro Ottaiano, et al.
The Oncologist
|
December 8, 2020
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer
Sandro Pignata, Giovanni Scambia, Alessandro Villanucci, et al.
Current Oncology (Toronto, Ont.)
|
July 27, 2022
An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
Michele Bartoletti, Giorgio Giorda, Alessandra Viel, et al.
Cancer Chemotherapy and Pharmacology
|
March 7, 2009
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
Carmela Pisano, Alessandro Morabito, Roberto Sorio, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 20, 2017
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project
Marilena Di Napoli, Chiara Della Pepa, Laura Arenare, et al.
EMBO Molecular Medicine
|
August 6, 2017
CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation
Alessandra Dall'Acqua, Maura Sonego, Ilenia Pellizzari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 2, 2014
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer
Martin R Stockler, Felix Hilpert, Michael Friedlander, et al.
Page
of 6